We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $132.87, demonstrating a +1.75% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.18%, and the technology-centric Nasdaq increased by 0.31%.
Coming into today, shares of the kidney dialysis provider had lost 5.2% in the past month. In that same time, the Medical sector lost 0.38%, while the S&P 500 gained 3.15%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. The company is predicted to post an EPS of $3.29, indicating a 27.03% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.4 billion, up 4.27% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.93 per share and a revenue of $13.46 billion, signifying shifts of +12.91% and +5.01%, respectively, from the last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. DaVita HealthCare is currently a Zacks Rank #2 (Buy).
Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 11.95. This expresses a discount compared to the average Forward P/E of 21.36 of its industry.
We can additionally observe that DVA currently boasts a PEG ratio of 0.94. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 1.96.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 41, finds itself in the top 17% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $132.87, demonstrating a +1.75% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.18%, and the technology-centric Nasdaq increased by 0.31%.
Coming into today, shares of the kidney dialysis provider had lost 5.2% in the past month. In that same time, the Medical sector lost 0.38%, while the S&P 500 gained 3.15%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. The company is predicted to post an EPS of $3.29, indicating a 27.03% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.4 billion, up 4.27% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.93 per share and a revenue of $13.46 billion, signifying shifts of +12.91% and +5.01%, respectively, from the last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. DaVita HealthCare is currently a Zacks Rank #2 (Buy).
Looking at its valuation, DaVita HealthCare is holding a Forward P/E ratio of 11.95. This expresses a discount compared to the average Forward P/E of 21.36 of its industry.
We can additionally observe that DVA currently boasts a PEG ratio of 0.94. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Outpatient and Home Healthcare industry was having an average PEG ratio of 1.96.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 41, finds itself in the top 17% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.